| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/22/2018 | SEIDENBERG BETH C | Director | Other | Common Stock | 4.3M | $50.00 | $213.3M | By KPCB Holdings, Inc., as nominee | 06/22/2018 |
| 06/22/2018 | SEIDENBERG BETH C | Director | Disposition | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 06/22/2018 |
| 06/22/2018 | ORBIMED ADVISORS LLC | 10% Owner | Other | Common Stock | 3.7M | $50.00 | $185.5M | By OrbiMed Private Investments IV, LP | 06/22/2018 |
| 06/22/2018 | ORBIMED ADVISORS LLC | 10% Owner | Other | Common Stock | 409.5k | $50.00 | $20.5M | By OrbiMed Private Investments V, LP | 06/22/2018 |
| 06/22/2018 | CROSS HERB | CFO | Disposition | Stock Option (right to buy) | 240.7k | $6.97 | $1.7M | | 06/22/2018 |
| 06/22/2018 | Legault Pierre | Director | Disposition | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 06/22/2018 | Legault Pierre | Director | Disposition | Stock Option (right to buy) | 55.8k | $6.73 | $375.5k | | 03/26/2018 |
| 06/22/2018 | Cui Xiangmin | Director | Other | Common Stock | 1.2M | $50.00 | $60.7M | By Decheng Capital China Life Sciences USD Fund II, L.P. | 06/22/2018 |
| 06/22/2018 | Cui Xiangmin | Director | Disposition | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 06/22/2018 |
| 06/22/2018 | GORDON CARL L | Director | Other | Common Stock | 3.7M | $50.00 | $185.5M | By OrbiMed Private Investments IV, LP | 06/22/2018 |
| 06/22/2018 | GORDON CARL L | Director | Other | Common Stock | 409.5k | $50.00 | $20.5M | By OrbiMed Private Investments V, LP | 06/22/2018 |
| 06/22/2018 | GORDON CARL L | Director | Disposition | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 06/22/2018 |
| 06/22/2018 | Kleiner Perkins Caufield & Byers XIV, LLC | 10% Owner | Other | Common Stock | 4.3M | $50.00 | $213.3M | By KPCB Holdings, Inc., as nominee | 06/22/2018 |
| 06/22/2018 | VAN VLASSELAER PETER | President and CEO | Other | Common Stock | 809.9k | $50.00 | $40.5M | | 06/22/2018 |
| 06/22/2018 | VAN VLASSELAER PETER | President and CEO | Disposition | Stock Option (right to buy) | 190.6k | $1.32 | $251.4k | | 06/22/2018 |
| 06/22/2018 | VAN VLASSELAER PETER | President and CEO | Disposition | Stock Option (right to buy) | 220.5k | $1.32 | $290.8k | | 06/22/2018 |
| 06/22/2018 | VAN VLASSELAER PETER | President and CEO | Disposition | Stock Option (right to buy) | 398.2k | $3.30 | $1.3M | | 06/22/2018 |
| 06/22/2018 | VAN VLASSELAER PETER | President and CEO | Disposition | Stock Option (right to buy) | 216.2k | $6.97 | $1.5M | | 06/22/2018 |
| 06/22/2018 | Leveque Joseph | Chief Medical Officer | Disposition | Stock Option (right to buy) | 288.8k | $6.97 | $2M | | 06/22/2018 |
| 06/22/2018 | Xu Stella | Director | Disposition | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 06/22/2018 |
| 06/22/2018 | Xu Stella | Director | Other | Common Stock | 404.9k | $50.00 | $20.2M | By Quan Venture Fund I, L.P. | 06/22/2018 |
| 06/22/2018 | Rizvi Naiyer | Director | Disposition | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 06/22/2018 |
| 06/22/2018 | Rizvi Naiyer | Director | Disposition | Stock Option (right to buy) | 19.1k | $6.73 | $128.9k | | 06/22/2018 |
| 03/26/2018 | Rizvi Naiyer | Director | Grant | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 03/26/2018 | GORDON CARL L | Director | Grant | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 03/26/2018 | Xu Stella | Director | Grant | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 03/26/2018 | Cui Xiangmin | Director | Grant | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 03/26/2018 | Legault Pierre | Director | Grant | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 03/26/2018 | SEIDENBERG BETH C | Director | Grant | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 01/30/2018 | Cui Xiangmin | Director | Conversion | Common Stock | 1.2M | $0.00 | $0 | By Decheng Capital China Life Sciences USD Fund II, L.P. | 01/30/2018 |
| 01/30/2018 | Cui Xiangmin | Director | Conversion | Series C-1 Convertible Preferred Stock | 1.2M | $0.00 | $0 | By Decheng Capital China Life Sciences USD Fund II, L.P. | 01/30/2018 |
| 01/30/2018 | GORDON CARL L | Director | Conversion | Common Stock | 3.7M | $0.00 | $0 | By OrbiMed Private Investments IV, LP | 01/30/2018 |
| 01/30/2018 | GORDON CARL L | Director | Conversion | Common Stock | 409.5k | $0.00 | $0 | By OrbiMed Private Investments V, LP | 01/30/2018 |
| 01/30/2018 | GORDON CARL L | Director | Conversion | Series A Convertible Preferred Stock | 1.8M | $0.00 | $0 | By OrbiMed Private Investments IV, LP | 01/30/2018 |
| 01/30/2018 | GORDON CARL L | Director | Conversion | Series B Convertible Preferred Stock | 1.2M | $0.00 | $0 | By OrbiMed Private Investments IV, LP | 01/30/2018 |
|